Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTx-024 in ER+/AR+ metastatic breast cancer
NCT02463032Phase 2Completed
- Sponsor
- GTx
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enobosarm in breast cancer (2 arms), sponsored by GTx. Primary endpoint: Clinical Benefit Rate at 24 weeks. Started Aug 2015; status: completed.
02
Drugs
enobosarm
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02463032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463032.